Amylin Pharmaceuticals
Christine Mendoza is an accomplished Principal Scientist with significant experience in the pharmaceutical industry. Currently at Amylin Pharmaceuticals since 2003, Christine has excelled in API Development, overseeing the clinical manufacturing of protein and peptide APIs and managing contract manufacturing organizations through various stages of process development. In a prior role at Amylin, Christine played a crucial role in transferring analytical assays for a commercial peptide drug product and contributed to achieving GMP Quality Control status in the internal development lab. Christine began their career at Corvas International, Inc., where management and scientific positions were held over a decade. Christine holds a Ph.D. in Biochemistry from the University of California, Berkeley, and a B.A. in Biochemistry from Rice University.
Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs.Develops a line of diagnostic and therapeutic products for diabetics.Working towards a cure for diabetes by challenging science, changing lives. Amylin employees are dedicated in their ability to "think outside thebox". Because of our commitment of constantly finding newer and better ways to treat diabetes, we come to work each day feeling like we CAN make a difference in our world.